Genomatica Annual Revenue, Number of Employees, Growth and Funding

Claim your profile


Total Funding:$191.1M
Lead Investor(s):Casdin Capital
Claim your profile

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Genomatica's estimated annual revenue is currently $34.7M per year.
  • Genomatica received $90.0M in venture funding in October 2018.
  • Genomatica's estimated revenue per employee is $210,000
  • Genomatica's total funding is $191.1M.

Employee Data

  • Genomatica has 165 Employees.
  • Genomatica grew their employee count by 30% last year.
  • Genomatica currently has 8 job openings.

Executive Contacts

Christophe SchillingCEO/co-founder
Damien PerrimanSenior Vice President, Specialty Products
Nelson BartonVP Research/Development
Rainer WagesterPrincipal Scientist
Tae YangDirector Of Systems Bioengineering
Joe KuterbachVp Operations And Technology Transfer
Jason CraterManager, Scale-up & Technology Transfer
Lisa KennedyAssociate Director of Business Development
Inessa ShpakAccounting Manager
Michael JapsSenior Director, Process Technology

Genomatica is a widely-recognized technology leader for the chemical industry. We develop manufacturing processes that enable our licensee partners to produce the world's most widely-used chemicals a better way, from alternative feedstocks, with better economics and greater sustainability than petroleum-based processes. Genomatica has delivered the industry's first commercial biobased process for a high-volume intermediate chemical. Our GENO BDO process has produced thousands of tons of BDO and been licensed by BASF and Novamont. Multiple large chemical firms have publicly validated quality or described commercialization plans, including Invista (for its well-known Lycra® spandex), DSM, Lanxess, Toray, and Far Eastern New Century. Our biotechnology platform and over 500 patents and applications enable us to develop processes for additional major chemicals. The next is for butadiene, with Versalis and Braskem as partners, and over $100 million in industry support. We have also announced our program for nylon intermediates, including HMD, caprolactam and adipic acid. We've been honored to receive extensive recognition for our innovation, commercialization track record, and potential for broad impact. Recent examples include the Kirkpatrick Award, for the most noteworthy chemical engineering technology commercialized in the world, and the 2015 World Economic Forum Technology Pioneer award. See current job openings at

keywords:Biotechnology,Cleantech,Energy,Food & Beverages,Healthcare,Pharmaceuticals,Solar Power,Wind Power


Number of Employees


Revenue (est)


Current Jobs


Employee Growth %


Total Funding







NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Forensic Analyt...
Partner Energy
AEI Consultants
3Degrees Group
Natron Energy
Canadian Solar ...
San Diego Count...
Stillwater Scie...
Sierra Energy

Genomatica News

06/06/2019 - Bioengineering Company Genomatica Is Acquiring Assets From Biodiesel Firm To Expand Product Lines

Genomatica, which uses bacteria to manufacture chemicals from plants, announced Thursday that it is acquiring assets from the REG Life ...

06/06/2019 - Genomatica Acquires REG Life Sciences’ Assets

Adds capabilities to meet increasing demand for sustainable products. SAN DIEGO, June 06, 2019 (GLOBE NEWSWIRE) -- Genomatica, ...

06/06/2019 - Renewable Energy Group Completes Sale of REG Life ...

“We are pleased to be selling our Life Sciences' assets to Genomatica, who are well positioned to build upon the technical progress we have ...

Genomatica Funding

DateAmountRoundLead InvestorsReference
2010-03-29$15.0MCTPG BiotechArticle
2000-03-02$45.0MUndisclosedVantagePoint Venture PartnersArticle
2011-03-02$45.0MUndisclosedVantagePoint Venture PartnersArticle
2018-10-04$90.0MUndisclosedCasdin CapitalArticle

Genomatica Executive Hires

2010-09-14Bill BaumChairman/Chief Business Development OfArticle
2011-07-19Michael E. KeaneEVP/CFOArticle
2012-05-01Jeff LievenseEVP Process TechnologyArticle